The American Journal of Managed Care6h
FDA Approves Atrasentan for Proteinuria Reduction in Primary IgA Nephropathy
Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...
MedPage Today5h
IgA Nephropathy Drug With Novel Mechanism Wins FDA Approval
The FDA granted accelerated approval to atrasentan (Vanrafia) for the reduction of proteinuria in adults with primary ...
US FDA Approves Amgen's Uplizna as First Treatment for Rare Immune Disorder
The drug, also known as inebilizumab, has now become the first FDA-approved treatment for Immunoglobulin G4-related disease ...